10x Genomics launches FFPE Visium assay for research use

2021 06 10 15 05 1452 2021 06 10 10 X Genomics 400

10x Genomics has launched its new Visium Spatial Gene Expression assay for formalin-fixed, paraffin-embedded (FFPE) samples, which gives researchers the ability to assess the whole transcriptome across an entire FFPE tissue sample.

FFPE processing is challenging because of the inherent damage caused to nucleic acids during fixation. The product, which was developed based on requests from customers performing translational research, addresses this challenge by using new chemistry developed for the company's Visium platform that allows for massive throughput and next-generation sequencing of clinical research samples.

The Visium for FFPE assay features the following:

  • Unbiased whole-transcriptome analysis
  • Full tissue section coverage that removes analysis boundaries associated with predefined regions of interest
  • High cellular resolution with one to 10 cells per spot depending on tissue type
  • Compatibility with histological analyses, allowing for morphological context overlaid with transcriptomic analysis
  • Ready-to-use assay kit, eliminating the need for specialized instrumentation

10x Genomics is now shipping the Visium for FFPE assay kit, which contains all the reagents and consumables needed for whole-transcriptome analysis in human FFPE tissue sections.

Expression of triple-positive ductal carcinoma in situ (TPDCIS) markers compared to immunohistochemistry staining of TPDCIS. Image courtesy of 10x Genomics.Expression of triple-positive ductal carcinoma in situ (TPDCIS) markers compared to immunohistochemistry staining of TPDCIS. Image courtesy of 10x Genomics.
Page 1 of 40
Next Page